| Literature DB >> 31227794 |
Taylon Felipe Silva1, Virgínia Márcia Concato2, Fernanda Tomiotto-Pellissier2,3, Manoela Daiele Gonçalves4, Bruna Taciane da Silva Bortoleti2,3, Eliandro Reis Tavares5, Lucy Megumi Yamauchi5, Cintia Magalhães Carvalho Grion6, Andréa Name Colado Simão7, Milena Menegazzo Miranda-Sapla2, Idessania Nazareth Costa2, Wander Rogério Pavanelli2, Ivete Conchon-Costa2.
Abstract
CMV reactivation has been widely associated with bacterial sepsis and occurs in approximately 30% of these individuals, is associated with a longer ICU stay, prolongation of the need for mechanical ventilation, and over 80% increase in the mortality rate, being directly associated with severe organ dysfunction and hemodynamic imbalance. Thus, the aim of this study was to evaluate the role of CMV reactivation in sepsis progression. The overall occurrence of cytomegalovirus reactivation in the cohort was 17.58%. Was observed an increase in plasma levels of NO, reduction of percentage of free days of mechanical ventilation and arterial pH, as well as changes in coagulation parameters in the reactivated group. There was also a significant increase in IL-10, creatinine, urea levels and reduction of 24-hour urine output. These variables still correlated with viral load, demonstrating an association between the reactivation process and kidney failure present in sepsis. The reactivated group still had 2.1 times the risk of developing septic shock and an increase in the mortality rates. CMV is reactivated in sepsis and these patients presented a higher risk of developing septic shock and higher mortality rates and our data suggest that IL-10 and NO may be involved in this process.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31227794 PMCID: PMC6588619 DOI: 10.1038/s41598-019-45390-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Methodological flow chart. Demonstration of patients excluded/included in the study and distribution of the groups evaluated.
Characteristics of 56 patients seven days after diagnosis of sepsis with or without cytomegalovirus reactivation.
| Variables | All patients N = 56 | Non-Reactivated N = 46 | Reactivated N = 10 | p-value |
|---|---|---|---|---|
| Age (years)a | 72 (52–81) | 70 (50–83) | 74 (69–78) | 0.646 |
| Genderb | 1.000 | |||
| Male | 31 (55) | 25 (54) | 6 (60) | |
| Female | 25 (45) | 21 (46) | 4 (40) | |
| Length of stay in hospital (dias)a | 17 (13–30) | 17 (14–30) | 16 (11–34) | 0.586 |
| SOFAa | 6 (4–10) | 6 (3–9) | 10 (7–11) | 0.020 |
| APACHE IIa | 20 (17–25) | 20 (17–24) | 25 (21–26) | 0.124 |
| Glasgow scalea | 10 (7–15) | 10 (7–15) | 8 (3–8) | 0.037 |
| Sodium (mEq/dL)a | 139 (136–142) | 140 (136–143) | 138 (136–141) | 0.414 |
| Potassium (mEq/dL)c | 3.82 ± 0.78 | 3.77 ± 0.75 | 4.06 ± 0.91 | 0.298 |
| Serum bilirubin (mg/dL)a | 0.4 (0.26–0.7) | 0.5 (0.27–0.75) | 0.39 (0.24–0.68) | 0.656 |
| WBC (mm³)c | 12833 ± 6574 | 13163 ± 6940 | 11345 ± 4562 | 0.537 |
| Typical lymphocytesc | 4399 ± 926.9 | 4366 ± 898 | 4549 ± 1090 | 0.575 |
| IL-6 (pg/mL)a | 10.2 (5.7–19.3) | 10.5 (5.8–19.4) | 9.9 (5.5–35.2) | 0.922 |
| IL-17a (pg/mL)a | 52.9 (35.5–61.5) | 48.7 (32.6–61.6) | 55.7 (46.4–62.7) | 0.231 |
| Septic shockb | 35 (63) | 26 (57) | 9 (90) | 0.012 |
| 28-days of mortalityb | 17 (30) | 11 (24) | 6 (60) | 0.052 |
| 180-days of mortalityb | 32 (57) | 24 (52) | 8 (80) | 0.161 |
SOFA - Sequential organ failure assessment.
APACHE II - Acute physiology and chronic health evaluation II.
WBC – White blood cells.
IL- interleukin.
aMann Whitney’s U-test, data show as median (25th and 75th percentile).
bFisher’s exact test, absolute number (n) (percentage of the group).
cStudent’s t-test data show as mean ± standart desviation.
Figure 2Analysis of clinical and laboratory changes related to CMV reactivation on the seventh day after diagnosis of sepsis. Non-reactivated group (NR). Reactivated group (R). (A) levels of plasmatic NO. (B) percentage of free days from mechanical ventilation (%FDMV). (C,D), arterial pH and partial pressure of arterial carbon dioxide (pCO2). (E) Counts of total platelets per cubic millimeter x10³. (F) Percentage of hematocrit in venous blood. (G) activated partial thromboplastin time (APTT), and (H) levels of serum C-reactive protein. All data were analyzed through Student’s T test, except %FDMV and % hematocrit which were evaluated by Mann Whitney’s U test. Data show as median at line and mean in +, with 25th and 75th percentile and bars represent the minimum and maximum values.
Figure 3Effect of CMV reactivation on IL-10 levels and renal evaluation parameters. Non-reactivated (NR). Reactivated group (R). Comparison between the groups for plasma level of IL-10 (A), serum levels of creatinine (B), and urea (D), 24-hour urine output (24hUO) (C) and its correlation with viral load in the reactivated group. (E) Heat map of the r-value through correlation between the variables. Below the cut line are presented the values of the reactivated group and the values of the non-reactivated group, p-values were categorized through NS (p>0.05); *(p ≤ 0.05); **(p ≤ 0.01); ***(p≤0.001); ****(p≤0.0001). All data were assesed through Student's T test and Pearson’s correlation. Data show as median at line and mean in +, with 25th and 75th percentile and bars represent the minimum and maximum values.
Figure 4Survival curves among septic patients with or without CMV reactivation. (A,B) Kaplan-Meier survival analysis (p-value through Log-Rank) comparing septic patients with (dashed line) or without (continuous line) CMV reactivation. (A) 28-day mortality. (B) 180-day mortality.